IL314188A - Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof - Google Patents
Solid crystalline forms of helicase-primase inhibitors and process of preparation thereofInfo
- Publication number
- IL314188A IL314188A IL314188A IL31418824A IL314188A IL 314188 A IL314188 A IL 314188A IL 314188 A IL314188 A IL 314188A IL 31418824 A IL31418824 A IL 31418824A IL 314188 A IL314188 A IL 314188A
- Authority
- IL
- Israel
- Prior art keywords
- helicase
- preparation
- crystalline forms
- solid crystalline
- primase inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820 | 2022-01-17 | ||
| EP22170332 | 2022-04-27 | ||
| PCT/EP2023/050883 WO2023135303A1 (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314188A true IL314188A (en) | 2024-09-01 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314188A IL314188A (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (https=) |
| EP (1) | EP4466255A1 (https=) |
| JP (1) | JP2025502300A (https=) |
| KR (1) | KR20240134979A (https=) |
| AU (1) | AU2023206628A1 (https=) |
| CA (1) | CA3246779A1 (https=) |
| CL (1) | CL2024002124A1 (https=) |
| IL (1) | IL314188A (https=) |
| MX (1) | MX2024008821A (https=) |
| PY (1) | PY2302301A (https=) |
| TW (1) | TW202337444A (https=) |
| UY (1) | UY40111A (https=) |
| WO (1) | WO2023135303A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319024A (en) * | 2022-08-29 | 2025-04-01 | Assembly Biosciences Inc | Pharmaceutical preparations for the herpes virus |
| IL325911A (en) | 2023-07-17 | 2026-03-01 | Innovative Molecules Gmbh | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| MX2020003369A (es) | 2017-10-05 | 2020-07-29 | Innovative Molecules Gmbh | Enantiomeros de tiazoles sustituidos como compuestos antivirales. |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| KR20230131177A (ko) | 2020-10-29 | 2023-09-12 | 이노베이티브 몰리큘스 게엠베하 | 항바이러스 화합물로서 중수소화된 아미노티아졸 화합물 |
-
2023
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240134979A (ko) | 2024-09-10 |
| MX2024008821A (es) | 2024-07-29 |
| WO2023135303A1 (en) | 2023-07-20 |
| US20250115565A1 (en) | 2025-04-10 |
| PY2302301A (es) | 2023-10-31 |
| TW202337444A (zh) | 2023-10-01 |
| UY40111A (es) | 2023-08-15 |
| CA3246779A1 (en) | 2023-07-20 |
| AU2023206628A1 (en) | 2024-08-01 |
| EP4466255A1 (en) | 2024-11-27 |
| JP2025502300A (ja) | 2025-01-24 |
| CL2024002124A1 (es) | 2024-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL314188A (en) | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof | |
| EP4216953A4 (en) | CRYSTALLINE POLYMORPH FORM A OF A JAK INHIBITOR AND METHOD FOR ITS PREPARATION | |
| IL326463A (en) | Crystalline forms of PI3K inhibitor and its uses | |
| CY1126929T1 (el) | Κρυσταλλικο υδροβρωμικο αλας της 5-μεο-dmt | |
| IL316075A (en) | Crystalline form of lenifranor | |
| IL287668A (en) | Crystalline forms of a btk inhibitor | |
| IL317847A (en) | Salts of SOS1 inhibitors | |
| EP4210833A4 (en) | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR | |
| IL315457A (en) | Solid forms, salts and preparation processes of the Sidikii2 inhibitor | |
| IL321053A (en) | Crystalline forms of HER2 inhibitor | |
| IL325861A (en) | Crystalline forms of menin inhibitor | |
| IL317006A (en) | Prodrugs of 3STAT inhibitors | |
| EP4471032A4 (en) | ACID SALT OR CRYSTALLINE FORM OF NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD AND USE THEREOF | |
| IL325911A (en) | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds | |
| EP4582084A4 (en) | CRYSTALLINE FORM OF A KETOAMIDE DERIVATIVE AND ITS PREPARATION PROCESS | |
| IL320431A (en) | Crystalline forms of zibagen hydrochloride and process for their preparation | |
| EP4624469A4 (en) | CRYSTALLINE FORM OF QUINOLEIN AMINE COMPOUND AND ITS PREPARATION PROCESS | |
| CA3283566A1 (en) | Crystalline form of midazolam hydrochloride | |
| HK40122705A (en) | Salts and polymorphs of certain mcl-1 inhibitors | |
| CA3298937A1 (en) | Micronized crystalline hydrochloride salts of antiviral helicase-primase inhibitor compounds | |
| CA3227010A1 (en) | Crystalline forms of ozanimod hydrochloride | |
| HK40118114A (en) | Prodrugs of stat3 inhibitors | |
| IL326433A (en) | Crystalline IRAK4 inhibitors | |
| IL325415A (en) | A new preparation method for a compound and a new crystalline form | |
| HK40121198A (en) | Crystalline forms and salts of a pi3k inhibitor and methods of making and methods of use thereof |